This first part of our dynamic learning experience is designed to enhance your ability to identify candidates for CAR T-cell therapy in chronic lymphocytic leukemia (CLL) and to deepen your knowledge of the latest clinical evidence for CAR T-cell therapy in relapsed/refractory CLL. Prepare to elevate your expertise and transform your approach to CLL management to improve patient outcomes.
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/accelerating-adoption-car-t-cell-therapy-into-clinical-practice-cll-treatment
- Start Date: 2024-07-10 05:00:00
- End Date: 2024-07-10 05:00:00
- Credit Details: IPCE Credits: 0.5 hours
AAPA Category 1 Credit™️: 0.5 hours
AMA PRA Category 1 Credit™️: 0.5 hours
Nursing: 0.5 hours
Pharmacy: 0.5 hours - Commercial Support: Source: Bristol-Myers Squibb Company - Amount: 49666.67 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest